Clinical trials: 2019-nCoV
2019-nCoV
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus…
- Trial name
- NCT04261426
- Testing
- Intravenous Immunoglobulin, Standard care
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Covid19, Sars-CoV-2 Infection
Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
South Africa recorded it's first coronavirus disease 2019 (COVID19) case on March 5, 2020. In response to the COVID19 outbreak World Health Organisation recommendations, South Africa implemented non-pharmaceutical…
- Trial name
- TRACE (NCT05119348)
- Testing
- STOPCOV
- Where
- South Africa
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Desmond Tutu HIV Foundation
Antithrombin III Deficiency, Covid19
Antithrombin III in Infectious Disease Caused by COVID-19
The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.
- Trial name
- NCT04899232
- Testing
- Antithrombin III
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Enrique Ginzburg
Novel Coronavirus Infection Pneumonia
A New Screening Strategy for 2019 Novel Coronavirus Infection
Since Dec 2019, over 70000 novel coronavirus infection pneumonia (NCIP) patients were confirmed. 2019 novel coronavirus (2019 nCoV) is a RNA virus, which spread mainly from person-to-person contact.
- Trial name
- NCT04281693
- Testing
- Standard screening strategy, New screening strategy
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Biological Availability, Healthy Participants
A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
Medicines that may have different names or be made in different ways but have the same effect on the body are called bioequivalent.
- Trial name
- NCT06397144
- Testing
- Paxlovid, Nirmatrelvir/ritonavir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Follow-up of Covid-19 Long Term Sequelae
The protocol, in accordance with the objectives of ORCHESTRA project - Work Package 2, aims at investigating the characteristics and determinants of COVID-19 long-term sequelae.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05097677
- Testing
- Not applicable (observational study)
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 7,599 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
COVID-19, Burnout
Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic
Healthcare systems around the world have faced tremendous stress because of the COVID-19 pandemic. Healthcare workers (HCWs) (ie.
- Conditions
- COVID-19, Burnout, Burnout, Professional, Work-related Illness
- Trial name
- NCT05394051
- Testing
- Positive Affect Regulation sKills (PARK)
- Where
- United States
- Volunteers
- 555 people, healthy volunteers welcome
- Sponsor
- Northwestern University
COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety…
- Trial name
- NCT04992273
- Testing
- casirivimab+imdevimab
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Regeneron Pharmaceuticals
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
- Trial name
- NCT05235347
- Testing
- Sotrovimab
- Where
- 4 sites in United States
- Sponsor
- Vir Biotechnology, Inc.
Covid19, SARS-CoV2 Infection
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- Conditions
- Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
- Trial name
- NCT05047783
- Testing
- Masitinib Mesylate
- Where
- 6 sites in France, Russia and 1 more
- Volunteers
- 78 people
- Sponsor
- AB Science
COVID-19
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted…
- Trial name
- NCT04452942
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EicOsis Human Health Inc.
Covid19
A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
COVID-19 morbidity and mortality has been associated with Cytokine Release Syndrome (CRS) and Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT04481685
- Testing
- ATI-450
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
COVID-19, SARS-CoV-2
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.
- Conditions
- COVID-19, SARS-CoV-2, 2019-nCoV, Pneumonia, Viral
- Trial name
- NCT04356508
- Testing
- Nivolumab
- Volunteers
- 15 people
- Sponsor
- Dr Gerry Gin Wai Kwok
COVID, Corona Virus Infection
Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers
The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have…
- Trial name
- NCT04424017
- Testing
- Specific anti-SARS-CoV-2 antibodies
- Where
- 2 sites in Egypt
- Volunteers
- 1,546 people
- Sponsor
- Egyptian Center for Research and Regenerative Medicine
COVID-19
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
- Trial name
- NCT05787418
- Testing
- HH-120 Nasal Spray
- Where
- 2 sites in China
- Volunteers
- 918 people
- Sponsor
- Huahui Health
ME/CFS, CFS/ME
Multi-Center Registry for ME/CFS
The ME/CFS study (MECFS-R) aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for ME/CFS at any age in Germany, which can be used for future clinical…
- Conditions
- ME/CFS, CFS/ME, ME/CFS Following EBV-associated Infectious Mononucleosis, ME/CFS Following COVID-19
- Trial name
- MECFS-R (NCT05778006)
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Technical University of Munich
COVID -19
C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.
During the peak of the second COVID -19 wave, the hospitals were over-crowded. Many COVID -19 positive patients had to stay at home and reach out to their family physicians for guidance.
- Trial name
- NCT04935515
- Testing
- Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins, Oral low dose steroid, Intravenous Antibiotics with Low dose steroid.
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Manimarane Arjunan, MD,DM (Cardiology)
Healthy Participants
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332…
- Trial name
- NCT05339334
- Testing
- PF-07321332/ritonavir
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19
Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
The purpose of this study is to describe balance deficits in patients post COVID-19. The information the investigators learn may help influence balance training exercises for patients post-COVID-19.
- Trial name
- NCT04914364
- Testing
- Balance assessments
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Duke University